A 12-week Study To Evaluate PF-06291874 Once a Day in Adults With T2DM Inadequately Controlled On Metformin



Status:Active, not recruiting
Conditions:Diabetes, Diabetes
Therapuetic Areas:Endocrinology
Healthy:No
Age Range:18 - 70
Updated:8/18/2016
Start Date:October 2015
End Date:August 2016

Use our guide to learn which trials are right for you!

A 12-week, Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of Once Daily Pf-06291874 Administration In Adults With Type 2 Diabetes Mellitus Inadequately Controlled On Metformin

The purpose of this study is to determine whether PF-06291874 is effective in the treatment
T2DM

This will be a randomized, double blind, stratified, placebo controlled, parallel group
study conducted in T2DM subjects receiving background metformin therapy. Subjects will
complete screening procedures to determine eligibility, followed by an 8 week metformin
stabilization period prior to randomization. In addition, subjects taking other OADs, in
combination with metformin, will undergo a washout during this period, in which non
metformin OAD medications will be temporarily discontinued for the duration of the trial.
Following confirmation of study eligibility criteria at randomization, subjects will be
stratified into 2 groups based on the use of concomitant statin therapy. Each stratum will
be randomized across treatment groups, such that the number of subjects taking concomitant
statin therapy and those not taking statin therapy will be approximately balanced across
treatment groups.

Inclusion Criteria:

1. Males or non-childbearing potential females between the ages of 18 (or the minimum
country specific age of consent if >18) and 70 years, inclusive, at the screening
visit (V1) with the diagnosis of T2DM;Female subjects who are not of childbearing
potential

2. Subjects who have been on a stable dose of metformin either alone or in combination
with one additional acceptable OAD

3. HbA1c at the Screen Visit (V1), as assessed by study specific central laboratory, is
7-11% if on metformin monotherapy; is 6.5-9.5% if on dual combination therapy
(metformin plus 1)

Exclusion Criteria:

1. Diagnosis of type 1 diabetes mellitus or secondary forms of diabetes;

2. Fasting plasma glucose levels >270 mg/dL (15.0 mmol/L) at the screening and run in
visit, (as assessed by study specific central laboratory) confirmed by a single
repeat, if deemed necessary

3. History of myocardial infarction, unstable angina, arterial revascularization,
stroke, New York Heart Association Functional Class III IV heart failure, or
transient ischemic attack within 6 months of screening;

4. Any medical condition possibly affecting study drug absorption (eg, gastrectomy or
any area of intestinal resection, active inflammatory bowel disease or pancreatic
insufficiency

5. Subjects with a creatinine clearance <60 mL/min as determined by the Cockcroft Gault
equation (listed below) using serum creatinine measured at screening, confirmed via a
single repeat, if deemed necessary

6. Subject with a positive result for hepatitis B surface antigen (HBsAg), hepatitis B
core antibodies (HBc Ab) or hepatitis C virus (HCV) antibodies

7. Screening seated systolic blood pressure >160 mm Hg and/or diastolic blood pressure
>105 mm Hg after at least a 5 minute rest. Blood pressure determined as the mean of
triplicate measurements collected with approximately 2 minutes of rest between
measurements

8. Screening supine 12 lead ECG demonstrating a corrected QT (QTc) >470 msec; or a QRS
interval >120 msec. If QTc exceeds 470 msec or QRS exceeds 120 msec, the ECG may be
repeated 2 more times with an interval of 2-4 minutes between each measurement and
the mean of the 3 values used to determine the subject's eligibility

9. Subjects with an arm circumference >52 cm measured at the midpoint of the length of
the upper arm;

10. History (within the last 6 months) of regular alcohol consumption exceeding 14 drinks
per week for men and 7 drinks a week for women. (1 drink = 5 ounces of wine (150 mL)
or 12 ounces (360 mL) of beer or 1.5 ounces (45 mL) of hard liquor);

11. Treatment with thiazolidinediones (TZDs), or subcutaneously administered anti
diabetic agents (eg, insulin, exenatide, liraglutide, pramlintide) within 6 weeks
prior to V1;

12. Subjects with a known hypersensitivity or intolerance to a glucagon receptor
antagonist, or known prior participation in a trial involving PF 06291874;
We found this trial at
33
sites
Katy, Texas 77450
562
mi
from
Katy, TX
Click here to add this to my saved trials
860 Peachwood Drive
DeLand, Florida 32720
(386) 740-0770
Site Overview Avail Clinical Research is a renowned and experienced clinical research site conducting Phase...
1123
mi
from
DeLand, FL
Click here to add this to my saved trials
175 Cross Keys Rd.
Berlin, New Jersey 08009
856-753-7335
1237
mi
from
Berlin, NJ
Click here to add this to my saved trials
2010 Wilshire Boulevard
Los Angeles, California 90057
213-413-2500
1170
mi
from
Los Angeles, CA
Click here to add this to my saved trials
2128 W Flagler St # 201
Miami, Florida 33144
1319
mi
from
Miami, FL
Click here to add this to my saved trials
7940 Floyd Curl Dr.
San Antonio, Texas 78229
210-949-0122
570
mi
from
San Antonio, TX
Click here to add this to my saved trials
1897 Palm Beach Lakes Boulevard
West Palm Beach, Florida 33409
561-689-0606
1282
mi
from
West Palm Beach, FL
Click here to add this to my saved trials
1085 N Harbor Blvd
Anaheim, California 92801
(714) 774-7777
Anaheim Clinical Trials, LLC Anaheim Clinical Trials (ACT) is a research center of excellence for...
1155
mi
from
Anaheim, CA
Click here to add this to my saved trials
Asheboro, North Carolina 27203
1006
mi
from
Asheboro, NC
Click here to add this to my saved trials
1028
mi
from
Brampton,
Click here to add this to my saved trials
Columbus, Ohio 43213
817
mi
from
Columbus, OH
Click here to add this to my saved trials
801 Monterey Street
Coral Gables, Florida 33134
1318
mi
from
Coral Gables, FL
Click here to add this to my saved trials
Eatontown, New Jersey 07724
1284
mi
from
Eatontown, NJ
Click here to add this to my saved trials
Fargo, North Dakota 58103
631
mi
from
Fargo, ND
Click here to add this to my saved trials
High Point, North Carolina 27265
991
mi
from
High Point, NC
Click here to add this to my saved trials
Honolulu, Hawaii 96814
3717
mi
from
Honolulu, HI
Click here to add this to my saved trials
Houston, Texas 77074
572
mi
from
Houston, TX
Click here to add this to my saved trials
569
mi
from
Houston, TX
Click here to add this to my saved trials
Indianapolis, Indiana 46260
643
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Las Vegas, Nevada 89120
959
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Marlton, New Jersey 08053
1238
mi
from
Marlton, NJ
Click here to add this to my saved trials
Metairie, Louisiana 70006
693
mi
from
Metairie, LA
Click here to add this to my saved trials
Orange, California 92868
1154
mi
from
Orange, CA
Click here to add this to my saved trials
1106
mi
from
Richmond, VA
Click here to add this to my saved trials
Roseville, California 95661
1269
mi
from
Roseville, CA
Click here to add this to my saved trials
Sandy Springs, Georgia 30328
796
mi
from
Sandy Springs, GA
Click here to add this to my saved trials
565
mi
from
Schertz, TX
Click here to add this to my saved trials
South Miami, Florida 33143
1320
mi
from
South Miami, FL
Click here to add this to my saved trials
Spring Valley, California 91978
1133
mi
from
Spring Valley, CA
Click here to add this to my saved trials
St. Louis, Missouri 63141
403
mi
from
St. Louis, MO
Click here to add this to my saved trials
Trenton, New Jersey 08611
1247
mi
from
Trenton, NJ
Click here to add this to my saved trials
Upland, California 91786
1135
mi
from
Upland, CA
Click here to add this to my saved trials
Walnut creek, California 94598
1317
mi
from
Walnut creek, CA
Click here to add this to my saved trials